Compare Stocks: CSBR, LAB, QSI, and CDXS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDXS Codexis	$1.46 +2.8%	$1.84	$0.96 ▼ $2.98	$159.88M	2.52	1.15 million shs	757,828 shs
CSBR Champions Oncology	$5.22 -1.1%	$5.51	$4.83 ▼ $8.74	$73.49M	0.4	8,334 shs	10,920 shs
LAB Standard BioTools	$0.69 +1.7%	$0.79	$0.63 ▼ $1.72	$264.56M	1.37	1.59 million shs	1.76 million shs
QSI Quantum-Si	$0.77 +0.7%	$0.81	$0.69 ▼ $3.10	$166.57M	3.25	2.89 million shs	896,354 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDXS Codexis	+2.82%	-8.18%	+0.69%	-42.97%	-39.42%
CSBR Champions Oncology	-1.14%	+5.88%	-1.51%	-7.61%	-25.16%
LAB Standard BioTools	+1.72%	+6.79%	-12.57%	-40.39%	-46.86%
QSI Quantum-Si	+0.66%	-1.79%	+1.26%	-27.05%	-28.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDXS Codexis	$1.46 +2.8%	$1.84	$0.96 ▼ $2.98	$159.88M	2.52	1.15 million shs	757,828 shs
CSBR Champions Oncology	$5.22 -1.1%	$5.51	$4.83 ▼ $8.74	$73.49M	0.4	8,334 shs	10,920 shs
LAB Standard BioTools	$0.69 +1.7%	$0.79	$0.63 ▼ $1.72	$264.56M	1.37	1.59 million shs	1.76 million shs
QSI Quantum-Si	$0.77 +0.7%	$0.81	$0.69 ▼ $3.10	$166.57M	3.25	2.89 million shs	896,354 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDXS Codexis	+2.82%	-8.18%	+0.69%	-42.97%	-39.42%
CSBR Champions Oncology	-1.14%	+5.88%	-1.51%	-7.61%	-25.16%
LAB Standard BioTools	+1.72%	+6.79%	-12.57%	-40.39%	-46.86%
QSI Quantum-Si	+0.66%	-1.79%	+1.26%	-27.05%	-28.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDXS Codexis	2.25	Hold	$6.50	345.21% Upside
CSBR Champions Oncology	1.00	Sell	N/A	N/A
LAB Standard BioTools	1.67	Reduce	$1.35	96.94% Upside
QSI Quantum-Si	2.00	Hold	$1.00	30.55% Upside

Current Analyst Ratings Breakdown

Latest CSBR, LAB, QSI, and CDXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	CDXS Codexis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	QSI Quantum-Si	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	CDXS Codexis	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
8/17/2026	CDXS Codexis	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$9.00 ➝ $8.00
8/14/2026	QSI Quantum-Si	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	QSI Quantum-Si	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	LAB Standard BioTools	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
7/21/2026	LAB Standard BioTools	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/21/2026	QSI Quantum-Si	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	CDXS Codexis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	QSI Quantum-Si	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDXS Codexis	$77.68M	2.06	N/A	N/A	$0.30 per share	4.87
CSBR Champions Oncology	$59.42M	1.22	$0.01 per share	362.98	$0.29 per share	18.00
LAB Standard BioTools	$85.33M	3.15	N/A	N/A	$1.38 per share	0.50
QSI Quantum-Si	$2.44M	68.71	N/A	N/A	$0.82 per share	0.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDXS Codexis	-$43.97M	-$0.34	N/A	N/A	N/A	-39.55%	-74.36%	-23.58%	11/5/2026 (Estimated)
CSBR Champions Oncology	-$1.17M	-$0.08	N/A	N/A	N/A	-1.87%	-27.48%	-3.84%	9/14/2026 (Estimated)
LAB Standard BioTools	-$74.90M	$0.22	3.12	N/A	N/A	100.36%	-7.57%	-6.14%	11/3/2026 (Estimated)
QSI Quantum-Si	-$101.34M	-$0.46	N/A	N/A	N/A	-6,138.26%	-47.12%	-43.18%	11/4/2026 (Estimated)

Latest CSBR, LAB, QSI, and CDXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/14/2026	Q1 2027	CSBR Champions Oncology	-$0.01	N/A	N/A	N/A	$15.05 million	N/A
8/13/2026	Q2 2026	QSI Quantum-Si	-$0.1133	-$0.11	+$0.0033	-$0.11	$0.30 million	$0.34 million
8/11/2026	Q2 2026	CDXS Codexis	-$0.1417	-$0.13	+$0.0117	-$0.13	$13.82 million	$14.92 million
8/5/2026	Q2 2026	LAB Standard BioTools	-$0.0128	-$0.07	-$0.0573	-$0.07	$20.80 million	$20.10 million
7/27/2026	Q4 2026	CSBR Champions Oncology	-$0.05	$0.01	+$0.06	-$0.05	$12.89 million	$13.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDXS Codexis	N/A	N/A	N/A	N/A	N/A
CSBR Champions Oncology	N/A	N/A	N/A	N/A	N/A
LAB Standard BioTools	N/A	N/A	N/A	N/A	N/A
QSI Quantum-Si	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDXS Codexis	1.03	3.06	2.99
CSBR Champions Oncology	N/A	0.96	0.96
LAB Standard BioTools	N/A	9.10	8.80
QSI Quantum-Si	N/A	9.97	9.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDXS Codexis	78.54%
CSBR Champions Oncology	41.30%
LAB Standard BioTools	53.74%
QSI Quantum-Si	39.90%

Insider Ownership

Company	Insider Ownership
CDXS Codexis	3.50%
CSBR Champions Oncology	46.98%
LAB Standard BioTools	26.81%
QSI Quantum-Si	22.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDXS Codexis	250	109.51 million	105.67 million	Optionable
CSBR Champions Oncology	143	13.92 million	7.38 million	Optionable
LAB Standard BioTools	620	392.58 million	287.33 million	Optionable
QSI Quantum-Si	150	218.88 million	170.64 million	Optionable

CSBR, LAB, QSI, and CDXS Headlines

Recent News About These Companies

Quantum‑Si Earnings Call: Proteus Delay, Runway Extended

August 22, 2026 | theglobeandmail.com

Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

August 18, 2026 | globenewswire.com

FY2026 EPS Estimates for Quantum-Si Lifted by HC Wainwright

August 18, 2026 | marketbeat.com

Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

Quantum-Si Q2 Earnings Call Highlights

August 13, 2026 | marketbeat.com

Quantum-Si Incorporated (QSI) Reports Q2 Loss, Tops Revenue Estimates

August 13, 2026 | zacks.com

Quantum-Si (NASDAQ:QSI) Announces Quarterly Earnings Results

August 13, 2026 | marketbeat.com

Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update

August 13, 2026 | globenewswire.com

Stock Traders Purchase Large Volume of Call Options on Quantum-Si (NASDAQ:QSI)

August 13, 2026 | marketbeat.com

Quantum-Si Q2 2026 earnings preview

August 12, 2026 | msn.com

Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026

July 27, 2026 | globenewswire.com

Why Quantum-Si incorporated’s (QSI) Stock Is Up 5.02%

July 1, 2026 | aaii.comA

Quantum-Si (NASDAQ:QSI) CEO Jeffrey Alan Hawkins Sells 11,311 Shares

June 25, 2026 | insidertrades.com

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 16, 2026 | businesswire.com

Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™

June 10, 2026 | rutlandherald.comR

Why Quantum-Si incorporated’s (QSI) Stock Is Down 7.81%

June 8, 2026 | aaii.comA

Quantum-Si Announces the Expansion of the Proteus™ Roadshow

June 3, 2026 | finance.yahoo.com

Quantum-Si Announces the Expansion of the Proteus™ Roadshow

June 3, 2026 | businesswire.com

Is Quantum-Si (NASDAQ:QSI) In A Good Position To Invest In Growth?

June 1, 2026 | finance.yahoo.com

Quantum-Si incorporated (QSI) Shareholder/Analyst Call Prepared Remarks Transcript

May 15, 2026 | seekingalpha.com

Alliance Global Partners Sticks to Its Buy Rating for Quantum-Si (QSI)

May 14, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CSBR, LAB, QSI, and CDXS Company Descriptions

Codexis NASDAQ:CDXS

$1.46 +0.04 (+2.82%)

As of 09/4/2026 04:00 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Champions Oncology NASDAQ:CSBR

$5.22 -0.06 (-1.14%)

As of 09/4/2026 04:00 PM Eastern

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Standard BioTools NASDAQ:LAB

$0.69 +0.01 (+1.72%)

As of 09/4/2026 04:00 PM Eastern

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Quantum-Si NASDAQ:QSI

$0.77 +0.01 (+0.66%)

As of 09/4/2026 04:00 PM Eastern

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CSBR, LAB, QSI, and CDXS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CSBR, LAB, QSI, and CDXS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CSBR, LAB, QSI, and CDXS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CSBR, LAB, QSI, and CDXS Company Descriptions

Codexis NASDAQ:CDXS

Champions Oncology NASDAQ:CSBR

Standard BioTools NASDAQ:LAB

Quantum-Si NASDAQ:QSI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CSBR, LAB, QSI, and CDXS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CSBR, LAB, QSI, and CDXS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CSBR, LAB, QSI, and CDXS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CSBR, LAB, QSI, and CDXS Company Descriptions

Codexis NASDAQ:CDXS

Champions Oncology NASDAQ:CSBR

Standard BioTools NASDAQ:LAB

Quantum-Si NASDAQ:QSI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools